Clinical Trials
12 trialsNCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT02310321 2025-09-02
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Astellas Pharma Inc
Phase 1/2 Completed
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02873338 2023-09-07
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
Jazz Pharmaceuticals
Phase 2 Completed
NCT02703272 2022-12-02
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 3 Terminated
NCT00620321 2019-09-09
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Eli Lilly and Company
Phase 2 Completed
NCT00878722 2015-07-28
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Valerio Therapeutics
Phase 1/2 Completed